HTG Molecular Diagnostics (NASDAQ:HTGM) received a $8.00 price target from equities researchers at HC Wainwright in a research note issued to investors on Thursday. The brokerage currently has a “buy” rating on the medical research company’s stock. HC Wainwright’s price objective would suggest a potential upside of 130.67% from the stock’s current price.
Several other research firms have also recently issued reports on HTGM. ValuEngine upgraded shares of HTG Molecular Diagnostics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 27th. Cantor Fitzgerald assumed coverage on shares of HTG Molecular Diagnostics in a research note on Thursday, September 20th. They issued a “buy” rating and a $7.00 target price for the company. Zacks Investment Research cut shares of HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 10th. Finally, Craig Hallum assumed coverage on shares of HTG Molecular Diagnostics in a research note on Monday, November 12th. They issued a “buy” rating and a $8.00 target price for the company. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $6.80.
Shares of HTGM traded up $0.04 during trading hours on Thursday, hitting $3.47. The stock had a trading volume of 73,135 shares, compared to its average volume of 301,387. The company has a debt-to-equity ratio of 0.42, a current ratio of 7.13 and a quick ratio of 6.93. HTG Molecular Diagnostics has a fifty-two week low of $1.71 and a fifty-two week high of $5.83. The stock has a market cap of $97.74 million, a P/E ratio of -1.94 and a beta of 2.00.
HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its earnings results on Thursday, November 8th. The medical research company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. HTG Molecular Diagnostics had a negative net margin of 74.94% and a negative return on equity of 83.42%. The firm had revenue of $4.71 million during the quarter, compared to analysts’ expectations of $5.14 million. Equities analysts expect that HTG Molecular Diagnostics will post -0.71 EPS for the current year.
A number of large investors have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in shares of HTG Molecular Diagnostics during the third quarter worth $215,000. BlackRock Inc. grew its holdings in shares of HTG Molecular Diagnostics by 322.8% during the second quarter. BlackRock Inc. now owns 73,044 shares of the medical research company’s stock worth $238,000 after buying an additional 55,769 shares in the last quarter. Symmetry Peak Management LLC purchased a new stake in shares of HTG Molecular Diagnostics during the third quarter worth $429,000. Acadian Asset Management LLC purchased a new stake in shares of HTG Molecular Diagnostics during the second quarter worth $353,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of HTG Molecular Diagnostics during the second quarter worth $650,000. Institutional investors own 46.55% of the company’s stock.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.
Further Reading: When is a capital gain realized?
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.